{"title":"Personalized cancer vaccines: what to ask","summary":"What “built for your tumor” means, what remains experimental, and what to check before committing.","body":"I am working on a personalized mRNA vaccine for my ALK-positive lung cancer. That is a project in progress. It is not proof that the vaccine will work, and it is not a treatment plan for someone else.\n\n## What it is trying to do\n\nA cancer treatment vaccine aims to help the immune system recognize features of cancer cells. That is different from a vaccine that prevents an infection which can cause cancer.\n\nIn my project, the team used normal and tumor sequencing, ranked candidate targets, and selected a personalized design. Design, manufacturing, permission to administer, and measuring the result are separate steps. Completing one does not guarantee the next.\n\n[My original October 14 account](https://x.com/kevinace/status/2110478875692302392) has the personal details. Treat the dates and plans there as a snapshot, not a live status report.\n\n## Six questions before you spend money\n\n1. **What exactly is the product?** mRNA, peptide and other approaches are not interchangeable. Who designs it, makes it and administers it?\n2. **What is the evidence for this situation?** Ask for human data in the relevant cancer and setting. Success in another disease or after surgery does not establish benefit for advanced disease.\n3. **How would access work?** Is there a clinical trial? If not, what lawful investigational route and institutional review would apply?\n4. **What are the risks and fallback plans?** Ask about expected and unexpected side effects, delays, manufacturing failure and interaction with current care.\n5. **What does the full cost include?** Separate design, manufacturing, testing, clinical administration, travel and follow-up. Get the refund and failure terms in writing.\n6. **How will benefit be assessed?** An immune response, a scan result and longer disease control are different outcomes. Agree on what will be measured and when.\n\n## Expanded access is not product approval\n\nThe FDA describes expanded access as a potential route to investigational treatment outside a trial when specified conditions are met. It is not available just because someone can pay. It requires clinical and regulatory review, and access is not guaranteed.\n\nPermission to use an investigational product does not mean the FDA has found it safe and effective for that use. Unexpected serious side effects are possible.\n\n## Where to start\n\nBring the questions to your oncologist or a specialist in your cancer. Check [clinical trials](/resources/clinical-trials/) and ask [FCCT](/companies/fcct/) for research support if useful. Do not delay established care while pursuing a speculative option.","topics":["emerging-research"],"capabilities":[],"sources":[{"id":"x-2110478875692302392","label":"My personalized cancer vaccine project","url":"https://x.com/kevinace/status/2110478875692302392","publisher":"Kevin Wimer on X","checkedAt":"2026-10-22","supports":"Personal experience, read in Kevin’s supplied X export. Not independent clinical evidence.","type":"experience"},{"id":"nci-vaccines","label":"Cancer treatment vaccines","url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","publisher":"National Cancer Institute","checkedAt":"2026-10-22","supports":"Treatment versus prevention, different vaccine approaches and potential side effects.","type":"official"},{"id":"fda-access","label":"Expanded access","url":"https://www.fda.gov/news-events/public-health-focus/expanded-access","publisher":"US Food and Drug Administration","checkedAt":"2026-10-22","supports":"Eligibility conditions, investigational status and risk; access is not marketing approval.","type":"official"}],"applicability":"For patients and caregivers preparing questions with their cancer care team.","limitations":"Personal experience plus general background. This page does not verify efficacy of Kevin’s investigational design, give a current treatment-status update, or establish eligibility for any access pathway.","disclosure":{"type":"none","text":"No paid placement. I have no investment, advisory role, paid partnership or other financial relationship with the twelve companies in this initial directory."},"reviewedAt":"2026-10-22","relatedIds":["bcbf518f-872e-434c-b031-3d6c266ceaa4","f7221927-6b87-4be3-9a7c-906768a192a5","0c5f1f8b-4545-4ee0-9c05-ce1d7fb984d7"],"assetIds":["0f8ec349-c4ed-40c2-bae4-93e17913f4da","1a012497-73fd-48c6-9095-0ded01ea0dd8"],"xDiscussion":"https://x.com/kevinace/status/2110478875692302392","relatedX":[],"facts":[],"id":"966ad3d5-e20a-40de-ba3d-cb072e57ebef","kind":"resource","slug":"cancer-vaccines","revision":"9a8b9625-3313-4c38-a4a1-eda8647afe59","canonicalUrl":"https://kevinwimer.com/resources/cancer-vaccines/","publishedAt":"2026-10-23T00:00:15.301Z","updatedAt":"2026-10-23T00:00:15.301Z","previewOnly":false,"illustrationAssetId":"0f8ec349-c4ed-40c2-bae4-93e17913f4da","shareImageAssetId":"1a012497-73fd-48c6-9095-0ded01ea0dd8"}